Mannitol formulation for integrin receptor antagonist

Details Mannitol formulation for integrin receptor antagonist Mannitol formulation for integrin receptor antagonist

A - Human Necessities

61

K

A61K 31/44 (2006.01) A61K 9/20 (2006.01)

Patent

CA 2499149

Disclosed are pharmaceutical compositions of an integrin .alpha..nu..beta.3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget~s disease.

L'invention concerne des compositions pharmaceutiques d'un antagoniste de récepteur d'intégrine .alpha.v.beta.3 contenant du mannitol en tant qu'agent de liaison. Ces compositions sont préparées par granulation par voie humide ou par formulation de tablette par compression directe. Ces formulations pharmaceutiques sont utiles en vue d'inhiber la résorption osseuse associée à l'ostéoporose, aux maladies osseuses métastasiques, à l'hypercalcémie maligne et à la maladie de Paget.

Affiliated with

Also associated with

Rating

Mannitol formulation for integrin receptor antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mannitol formulation for integrin receptor antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mannitol formulation for integrin receptor antagonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1843951